* If you want to update the article please login/register
Colorectal cancer accounts for just 10% of all cancers and is the second most common cause of cancer deaths. In about 20% of patients, the first clinical presentation as metastatic CRC occurs. In addition, up to half of patients with localized disease will eventually experience metastases. In the emergence of precision medicine, this review summarizes the changes in the clinical care of patients with mCRC. The next steps in the clinical management of mCRC will include comprehensive knowledge of tumor gene and protein expression profiling, as well as the implementation of the resulting dynamic shifts to a precision medicine-based continuum of care for each patient. This strategy may result in the identification of individual prognostic and predictive parameters, which may assist the clinician in selecting the most appropriate therapeutic strategy for each patient with mCRC.
In order to investigate more thoroughly the differential expression of epitranscriptomic RWE proteins in a matched pair of primary/metastatic colorectal cancer cells, namely SW480/SW620, we used a similar reaction monitoring based on cell culture's stable isotope labeling as a standard isotope labeling by amino acids. Some of those proteins with marked decrease in metastatic CRC cells, including NAT10, hnRNPC, and DKC1, were shown to play key roles in CRC and other forms of cancer metastasis.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions